Epizyme, Inc. (EPZM)
| Market Cap | 833.14M |
| Revenue (ttm) | 22.04M |
| Net Income (ttm) | -251.03M |
| Shares Out | 101.79M |
| EPS (ttm) | -2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $8.67 |
| Previous Close | $8.55 |
| Change ($) | 0.12 |
| Change (%) | 1.40% |
| Day's Open | 8.55 |
| Day's Range | 8.15 - 8.74 |
| Day's Volume | 1,262,271 |
| 52-Week Range | 6.70 - 22.00 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today ...
Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it w...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third subhead of release should read: Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Castration-Resistant Pr...
Epizyme (EPZM) delivered earnings and revenue surprises of -10.17% and 30.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Epizyme (NASDAQ:EPZM) rose 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 10.17% over the past year to ($0.65), which missed t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference
Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript
Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.
Epizyme (EPZM) delivered earnings and revenue surprises of 9.84% and -40.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business a...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...
Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call Transcript
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.
Epizyme A Buy For Tazverik And Epigenetic Platform
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.
Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.
Shares of Epizyme Inc. EPZM, +4.81% were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory ...
The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.
If you have cash to spare, these cancer stocks are set to soar.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced
Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2020 Results - Earnings Call Transcript
Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
About EPZM
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with... [Read more...]
| Industry Biotechnology | IPO Date May 31, 2013 |
| CEO Robert Bazemore | Employees 304 |
| Stock Exchange NASDAQ | Ticker Symbol EPZM |
Financial Performance
In 2020, Epizyme's revenue was $15.76 million, a decrease of -33.77% compared to the previous year's $23.80 million. Losses were -$231.69 million, 36.1% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 18.63, which is an increase of 114.88% from the latest price.